Oaktree Capital Management is a privately owned investment manager specializing in alternative investment strategies.
Business Model:
Revenue: $709.5M
Employees: 1,001-5,000
Oaktree Capital Management was acquired by
Brookfield Asset Management.
The acquisition happend on 2019-03-13.
Details of the transaction were not public
Address: 333 South Grand Avenue
City: Los Angeles
State: CA
Zip: 90071
Country: US
Oaktree’s mission is to provide highly professional management with a primary emphasis on risk control in a limited number of sophisticated investment specialties. Oaktree specializes in less efficient markets and alternative investments, and has extensive experience, an enviable track record, broad product range and substantial assets under management. They are dedicated to the achievement of consistent and superior performance without high risk. Their ultimate objective is investment success, the fruits of which are shared by Oaktree’s clients and personnel.
Contact Phone:
+12138306300
Contact Email:
Listed Exchange:
NYSE
IPO Date:
4/12/2012
IPO Valuation:
$1B
Ticker Symbol:
OAK
IPO Price:
$43/share
Amount Raised:
$380M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2021 | Thrasio | Series C | 0 |
2/2021 | Thrasio | Series C | 750M |
4/2020 | SunOpta | Post-IPO Equity | 0 |
10/2016 | SunOpta | Post-IPO Equity | 85M |
10/2022 | scPharmaceuticals | Post-IPO Debt | 100M |
4/2015 | ezbob | Debt Financing | 45.2M |
9/2020 | Universal Plant Services | Secondary Market | - |
1/2014 | Ten K Solar | Venture Round | 0 |
8/2021 | Environmental 360 Solutions E360S | Venture Round | - |
7/2019 | Singular | Venture Round | - |
9/2019 | Mission Lane | Debt Financing | 300M |
6/2019 | Costa Edutainment | Secondary Market | 45.5M |
10/2018 | Assembled Brands | Funding Round | 100M |
12/2021 | Cvent | Post-IPO Equity | 0 |
10/2018 | Blue Sky Private Equity | Post-IPO Debt | 35.9M |
11/2012 | Pulse Electronics | Post-IPO Equity | 102.7M |
4/2022 | BioXcel Therapeutics | Post-IPO Equity | 5M |
11/2021 | Elevate Brands | Venture Round | 0 |
2/2021 | Win Brands Group | Equity | 50M |
7/2017 | DDH1 | Venture Round | - |
12/2020 | System One | Private Equity Round | - |
1/2021 | Thrasio | Debt Financing | 0 |
12/2021 | HealthCare.com | Series C | 0 |
3/2016 | FortiFi | Series A | 75M |
3/2018 | Proserv | Private Equity Round | 50M |
6/2016 | Tribes | Venture Round | - |
3/2016 | ezbob | Series C | 28.8M |
2/2022 | b atomic | Seed | 1M |
5/2021 | Marinus Pharmaceuticals | Post-IPO Debt | 45M |
12/2019 | Marinus Pharmaceuticals | Equity | 30M |
10/2021 | Mission Lane | Debt Financing | 150M |
6/2019 | SHINE Medical Technologies | Debt | 50M |
1/2022 | ABC Technologies | Post-IPO Equity | 269.5M |
3/2022 | Impel NeuroPharma | Post-IPO Debt | 50M |
3/2013 | Charter Communications | Post-IPO Equity | - |
4/2020 | Airbnb | Debt Financing | 1B |
2/2022 | Draslovka | Private Equity Round | 0 |
12/2021 | Montana Renewables | Debt Financing | 300M |
11/2020 | REEF | Private Equity Round | 700M |
6/2019 | cure.fit | Series D | 120M |
9/2021 | Priority Power Management | Private Equity Round | 250M |
4/2022 | BioXcel Therapeutics | Post-IPO Debt | 135M |
7/2020 | M3M India Limited | Debt Financing | 76M |
12/2020 | BKV Corporation | Venture Round | 100M |
12/2021 | SiO2 Materials Science | Debt | 205M |
12/2020 | brumbrum | Debt Financing | 65M |
6/2021 | Primary Wave | Private Equity Round | - |
9/2016 | ICICI Prudential Life Insurance | Private Equity Round | 0 |
7/2016 | Array Technologies | Seed Round | - |
3/2021 | SumUp | Debt Financing | 0 |
8/2020 | Fortress Biotech | Post-IPO Debt | 60M |
10/2011 | Panrico SA | Debt Financing | - |
3/2021 | NN | Post-IPO Equity | 265M |
11/2016 | Sterling Lumber Company | Venture Round | - |
10/2021 | Thrasio | Series D | 0 |
4/2014 | Enplug | Seed Round | 0 |
3/2021 | RumbleON | Post-IPO Equity | 280M |
3/2016 | ProService Finteco | Private Equity Round | - |
7/2018 | cure.fit | Series C | 120M |
1/2022 | Unblocked | Seed Round | 0 |
10/2018 | Montrose | Private Equity Round | - |
2/2018 | Kudu Investment Management | Funding Round | 0 |
6/2004 | Infraworks | Series B | 7.5M |
9/2020 | Zzoomm Full Fibre Broadband | Series B | 128.7M |
4/2022 | BioXcel Therapeutics | Post-IPO Debt | 0 |
4/2022 | BioXcel Therapeutics | Post-IPO Equity | 0 |
3/2022 | Marinus Pharmaceuticals | Post-IPO Debt | 0 |
3/2022 | Impel NeuroPharma | Post-IPO Debt | 0 |
2/2022 | b atomic | Seed Round | 0 |
2/2022 | Draslovka | Private Equity Round | 0 |
1/2022 | Unblocked | Seed Round | 0 |
1/2022 | ABC Technologies | Post-IPO Equity | 0 |
12/2021 | SiO2 Materials Science | Debt Financing | 0 |
12/2021 | HealthCare.com | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|